Barclays PLC Boosts Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Barclays PLC raised its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 251.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 94,809 shares of the company’s stock after acquiring an additional 67,855 shares during the period. Barclays PLC’s holdings in Organogenesis were worth $271,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP increased its holdings in shares of Organogenesis by 8.0% in the third quarter. Wellington Management Group LLP now owns 241,648 shares of the company’s stock worth $691,000 after purchasing an additional 17,842 shares during the last quarter. State Street Corp grew its holdings in Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock valued at $4,175,000 after buying an additional 9,090 shares in the last quarter. Verition Fund Management LLC increased its stake in Organogenesis by 542.8% in the 3rd quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock worth $225,000 after acquiring an additional 66,448 shares during the last quarter. Captrust Financial Advisors purchased a new stake in shares of Organogenesis during the 3rd quarter worth approximately $36,000. Finally, FMR LLC raised its holdings in shares of Organogenesis by 34.2% during the 3rd quarter. FMR LLC now owns 173,595 shares of the company’s stock worth $496,000 after acquiring an additional 44,199 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Trading Up 0.3 %

ORGO stock opened at $3.34 on Tuesday. The firm has a fifty day moving average price of $3.50 and a 200 day moving average price of $3.10. Organogenesis Holdings Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $4.57. The firm has a market cap of $419.94 million, a PE ratio of -55.67 and a beta of 1.77. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period last year, the company posted $0.02 EPS. Sell-side analysts anticipate that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Gary S. Gillheeney sold 55,615 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $3.36, for a total transaction of $186,866.40. Following the sale, the chief executive officer now owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. This represents a 1.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 278,116 shares of company stock worth $991,190. Corporate insiders own 36.90% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.